Comment from Cure GM1 Foundation

Summary: The Cure GM1 Foundation supports the FDA's Plausible Mechanism Framework but requests clarifications to ensure it is modality-neutral and applies to ultra-rare diseases. They argue that the framework should explicitly include enzyme replacement therapies and be applicable to ultra-rare, genetically defined diseases beyond just patient-specific individualized therapies.